Patents Assigned to Transgenex Nanobiotech, Inc.
  • Patent number: 11319311
    Abstract: Synthesis and characterization of novel DACT forms suitable for pharmaceutical compositions in drug delivery systems to treat cancer in humans or a warm-blooded mammals. The novel forms include but not limited to cocrystals, salts, solvates of salts, and mixtures thereof.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: May 3, 2022
    Assignee: TRANSGENEX NANOBIOTECH, INC.
    Inventors: Mazen Hanna, Manomi Perera, Jiyu Yan, Andrew Hanna
  • Patent number: 11053254
    Abstract: Synthesis and characterization of novel crystalline mitomycin C forms suitable for pharmaceutical compositions in drug delivery systems to treat human or warm-blooded diseases.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 6, 2021
    Assignee: TRANSGENEX NANOBIOTECH INC.
    Inventors: Mazen Hanna, Manomi Perera, Jiyu Yan, Andrew Hanna
  • Patent number: 11016062
    Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 25, 2021
    Assignees: University of South Florida, TransGenex Nanobiotech, Inc.
    Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair, Tao Wang
  • Patent number: 10813935
    Abstract: Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: October 27, 2020
    Assignees: TRANSGENEX NANOBIOTECH, INC., University of South Florida
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Mark Howell, Rajesh Nair
  • Publication number: 20200141905
    Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.
    Type: Application
    Filed: December 20, 2019
    Publication date: May 7, 2020
    Applicants: University of South Florida, TransGenex Nanobiotech, Inc.
    Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair, Tao Wang
  • Patent number: 10520472
    Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: December 31, 2019
    Assignees: University of South Florida, TransGenex Nanobiotech, Inc.
    Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair, Tao Wang
  • Publication number: 20180045681
    Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.
    Type: Application
    Filed: August 21, 2017
    Publication date: February 15, 2018
    Applicants: University of South Florida, TransGenex Nanobiotech, Inc.
    Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair
  • Publication number: 20100105024
    Abstract: A rapid test kit may have a genetic probe, and antibody detecting probe or a combination of a genetic probe and an antibody detecting probe disposed within one or more test windows of the test kit. A cellulose filter paper membrane with a flow rate selected in a range of about 0.04 to about 0.4 ml/min/cm2 is used in one example. The test kit provides for rapid screening for DNA, RNA or fragments of DNA or RNA in a bodily fluid or antibodies indicating exposure to such DNA/RNA. The genetic probe may include single stranded DNA or a fragment of single stranded DNA, such as primer, immobilized on the filter paper, and a single stranded DNA, such as the same or a different primer, conjugated with a marker, such as a nanotube or nanoparticle. For example, a gold nanoparticle or a carbon nanotube may be used as a staining agent by conjugating the gold nanoparticle or the carbon nanotube to a genetic probe, such as a DNA primer capable of binding with a complementary DNA or viral RNA or a fragment of one of these.
    Type: Application
    Filed: April 16, 2009
    Publication date: April 29, 2010
    Applicant: Transgenex Nanobiotech, Inc.
    Inventors: Weidong Xu, Shyam Mohapatra, Arun Kumar